Immunohistochemical surveys have demonstrated moderate-to-strong NECTIN4 expression in 60.3% of bladder cancer cases (316/524), 52.3% of breast cancer cases (342/654), 36.6% of pancreatic cancer cases (60/164), 27.0% of lung cancer cases (167/618), 24.3% of esophageal cancer cases (44/181), 18.5% of head and neck cancer (HNC) cases (25/135) and 17.8% of ovarian cancer cases (21/118) (Challita-Eid et al., 2016). This evidence concerns the gene NECTIN4 and familial pancreatic carcinoma.